Head-to-head evidence
DWP16001 vs Tofogliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
DWP16001 · Enavogliflozin
Developed by Daewoong Pharmaceutical
NCT04634500 · Phase 3 · completed
This Phase 3 trial randomly assigned 200 people with type 2 diabetes to enavogliflozin or to dapagliflozin, with participants and investigators unaware of assignment. It was designed to show enavogliflozin was not worse than dapagliflozin at lowering HbA1c over 24 weeks, within a margin of 0.35 percentage points. It met that test: HbA1c fell by 0.80 percentage points on enavogliflozin against 0.75 on dapagliflozin, a difference of 0.04 points (95% CI -0.21 to 0.12).
Next expected readout: December 2026 · NCT06399835 (registry estimate)
Tofogliflozin · Apleway / Deberza
Developed by Kowa Company, Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DWP16001's landscape · Tofogliflozin's landscape